氧化低密度脂蛋白作为增强微卫星稳定结直肠癌免疫检查点抑制剂治疗的潜在目标
Xiaochun Zhang1, Xiaorui Ye2, Heiying Jin1,2
1The Second Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Antioxidants (Basel, Switzerland)
|June 26, 2025
概括
氧化低密度脂蛋白 (oxLDL) 在微卫星稳定结直肠癌 (MSS CRC) 中促进免疫检查点抑制剂 (ICI) 耐药性. 向oxLDL可能会克服这种耐药性,为MSS CRC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 氧化低密度脂蛋白 (oxLDL) 在微卫星稳定 (MSS) 和微卫星不稳定性高 (MSI) 的结直肠癌 (CRC) 中表现不同.
- 在MSS CRC中增加的oxLDL与瘤进展和免疫检查点抑制剂 (ICI) 的有效性降低相关.
研究的目的:
- 调查oxLDL在MSS CRC中介导ICI耐药性的作用.
- 阐明oxLDL对免疫抑制瘤微环境 (TME) 的分子机制.
- 探索潜在的治疗策略,以oxLDL作为MSS CRC.的向.
主要方法:
- 在CRC中对oxLDL表达和功能的文献进行系统审查.
- 通过oxLDL激活的分子通路的分析,包括LOX-1和CD36信号.
- 检查oxLDL对免疫细胞群和TME内的代谢重编程的影响.
主要成果:
- oxLDL激活的途径 (NF-κB,PI3K/Akt,MAPK) 促进免疫抑制细胞 (Tregs,MDSCs,M2巨细胞) 和抑制效应T细胞.
- oxLDL增强氧化应激并改变TME代谢 (脂肪酸氧化,糖解),导致营养竞争.
- 这些机制集体建立了一个免疫抑制环境,导致MSS CRC.中的ICI耐药性.
结论:
- oxLDL通过代谢重编程和免疫抑制在MSS CRC中驱动ICI耐药性方面发挥着关键作用.
- 了解oxLDL的机制为开发新型治疗策略提供了基础.
- 向oxLDL是一个有前途的途径,可以提高MSS CRC的免疫疗法疗效.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675


